GTCbio, San Diego
2016/01/25-2016/1/26
We invite you to GTCbio's Novel Immunotherapeutics Summit, which takes place on January 25 - 26, 2016 in San Diego, CA. The summit will bring together our usual balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the various topics below.
14th Cytokines & Inflammation
This conference has become an established meeting point for academic scientists, industry clinical developers, and government researchers to discuss complementary approaches in the field of cytokine biology. Some focused topics we will discuss include developments in the therapeutic application of cytokines and proposal of new targets, the complex relationship between the immune system and microbes in the homeostasis of mucosal tissues, novel means to modulate immune pathways to promote anti-tumor activity, and many more.
8th Immunotherapeutics & Immunomonitoring
Leading experts from the scientific and clinical arenas and industry will present novel findings and developments in the constantly-changing area of immunological assays and procedures. They will also discuss recent advances in immunotherapy as they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and tumor microenvironment. Potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories will also be discussed.
4th Immunogenicity & Immunotoxicity
We will provide guests with a better understanding of the ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Guests will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.
3rd Allergy, Asthma, & COPD
Our gathering is a forum for researchers in the field to share advances in topics ranging from basic scientific research to biomarkers and clinical development. We will take a look at diseases such as eosinophilic esophagitis and atopic dermatitis, along with disorders involving comorbidities like ACOS. Another area of interest includes biomarkers for understanding phenotypes in allergic diseases. This meeting is the ideal event for networking and discussion on progress towards therapeutic potential in these disease areas.
We hope to see you there!
Best regards,
|
|